Moleculin Biotech secured Mexican Patent No. 436849 while issuing 888,400 common shares through its ATM offering for $0.48 million. The patent remains in force until November 23, 2040, extending stated protection for its lung-targeted liposomal Annamycin technology and supporting the company’s stated long-term commercial opportunity.

Key Highlights

  • Mexican Patent No. 436,849 covers Moleculin Biotech’s lung-targeted liposomal Annamycin technology.
  • The company’s ATM offering generated $0.48 million in gross proceeds during September 2026.
  • Series I Warrants covering up to 37,130,001 common shares were issued on August 3, 2026.

Moleculin Biotech, Inc. (NASDAQ: MBRX) is a Pharmaceuticals: Major company. It secured Mexican Patent No. 436,849 for its lung-targeted liposomal Annamycin technology, while its ATM offering produced $0.48 million in aggregate gross proceeds from September share issuances. The patent remains effective until November 23, 2040.

Mexican Patent and ATM Issuance Details

Moleculin said the patent strengthens its international intellectual property protection for the Annamycin formulation designed to target pulmonary tumors and metastatic disease. The company described the grant as supporting longer-term exclusivity for the covered technology and broader development opportunities beyond hematologic malignancies. During September 2026, Moleculin issued 888,400 common shares through the ATM arrangement, with Roth acting as sales agent. After those issuances, 20,385,780 common shares will be outstanding. The update also revised the Economics of the Series I Warrants issued in the public offering on August 3, 2026. Those warrants can be exercised for up to 37,130,001 common shares and initially carried a $0.75 per-share exercise price. Following the ATM share issuance, the exercise price fell to $0.51 per share under the warrants’ anti-dilution provisions, subject to a floor price.